Key facts
- Armatus Bio’s last known valuation is $28.3M (Nov 2023).
- It has raised $14.8M; the latest was Later Stage VC ($3.0M) in May 2025.
- Notable investors include Jumpstart Ventures, Rev1 Ventures, CincyTech, Angel Physicians Fund, CMT Research Foundation — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Armatus Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Armatus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Armatus Bio
Developer of vectorized therapeutics designed to target and silence specific genes. The company uses genetic science and bioengineering to deliver therapies specifically targeting affected tissues in genetic neuromuscular diseases, enabling medical professionals to offer effective treatment options for patients with rare conditions.
- Sector
- Healthcare
- HQ
- Columbus, OH, United States
- Founded
- 2020
- Employees
- 7
- Website
- armatusbio.com/
- Ownership
- Privately Held (backing)
Armatus Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Armatus Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Armatus Bio in its N-PORT filings yet. We sweep new filings monthly.